Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway . Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor . Kinase partner for the type I interferon receptor IFNAR2 . In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins . Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors . .

Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1),JAK1 JAK1A JAK1B

P23458,P52332

3716

Human,Mouse,Rat

WB,IHC,IF,ICC,ELISA

WB 1:1000-5000
IHC 1:200-1:1000
IF 1:100-1:400
ICC 1:100-1:400
ELISA 1:5000-1:20000

JAK1(Phospho Tyr1034/1035) Antibody detects endogenous levels of JAK1 protein only when phosphorylated at Tyr1034/1035.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KEyyTV

133kDa

Rabbit

Monoclonal

M171

IgG,Kappa

Protein A

PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Store at -20℃. Stable for 12 months from date of receipt.